The North America Hospital-Acquired Infection Diagnostics Market is expected to witness market growth of 7.0% CAGR during the forecast period (2022-2028).
The healthcare establishment bears a duty to HAI prevention. Sterilization and disinfection guidelines should be followed by hospitals and healthcare personnel. Taking precautions to avoid HAIs can reduce the chance of catching them by significant percentage. Although, because of the nature of healthcare facilities, eliminating all nosocomial diseases is unachievable.
The risk of hospital-acquired illnesses is determined by the facility's infection control policies, the patient's immunological condition, and the community's presence of different pathogens. Immuno suppression, advanced age, duration of hospital stays, various underlying comorbidities, frequent trips to healthcare institutions, mechanical ventilator assistance, recent invasive surgeries, indwelling devices, and all of the things put person at risk for HAI if person stay in an intensive care unit (ICU). One of the greatest risk factors for developing antimicrobial resistance to various medicines is receiving intravenous antibiotics during the last 90 days. Other patients, healthcare workers, or the hospital environment are among the potential spreaders of the diseases.
A great progress has been made in preventing the spread of some healthcare-associated illness types with the sincere efforts of regional government and healthcare bodies, as per the Centers for Disease Control and Prevention (CDC) 2021, but still it has so much work to complete. On any particular day, one out of each and every 31 hospital patients in the United States has minimum one healthcare-related infection. North America, particularly the United States and Canada, has achieved great progress toward the shared objective of eliminating HAIs, and as an outcome, healthcare in this region is safer than it was even several years ago. The rise in chronic conditions like cardiovascular disease and others necessitates longer hospital stays, resulting in an increase in hospital-acquired infection incidents. As per American Health Association figures from 2020, multiple million hospital admissions occurred in 2019. It is vital to build on this accomplishment and continue to work on the removal of hospital-acquired infections.
The US market dominated the North America Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,422.1 million by 2028. The Canada market is estimated to grow at a CAGR of 9.5% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 8.5% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
The healthcare establishment bears a duty to HAI prevention. Sterilization and disinfection guidelines should be followed by hospitals and healthcare personnel. Taking precautions to avoid HAIs can reduce the chance of catching them by significant percentage. Although, because of the nature of healthcare facilities, eliminating all nosocomial diseases is unachievable.
The risk of hospital-acquired illnesses is determined by the facility's infection control policies, the patient's immunological condition, and the community's presence of different pathogens. Immuno suppression, advanced age, duration of hospital stays, various underlying comorbidities, frequent trips to healthcare institutions, mechanical ventilator assistance, recent invasive surgeries, indwelling devices, and all of the things put person at risk for HAI if person stay in an intensive care unit (ICU). One of the greatest risk factors for developing antimicrobial resistance to various medicines is receiving intravenous antibiotics during the last 90 days. Other patients, healthcare workers, or the hospital environment are among the potential spreaders of the diseases.
A great progress has been made in preventing the spread of some healthcare-associated illness types with the sincere efforts of regional government and healthcare bodies, as per the Centers for Disease Control and Prevention (CDC) 2021, but still it has so much work to complete. On any particular day, one out of each and every 31 hospital patients in the United States has minimum one healthcare-related infection. North America, particularly the United States and Canada, has achieved great progress toward the shared objective of eliminating HAIs, and as an outcome, healthcare in this region is safer than it was even several years ago. The rise in chronic conditions like cardiovascular disease and others necessitates longer hospital stays, resulting in an increase in hospital-acquired infection incidents. As per American Health Association figures from 2020, multiple million hospital admissions occurred in 2019. It is vital to build on this accomplishment and continue to work on the removal of hospital-acquired infections.
The US market dominated the North America Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $1,422.1 million by 2028. The Canada market is estimated to grow at a CAGR of 9.5% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 8.5% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Reagents & Consumables
- Instrument
By Infection Type
- Urinary Tract Infections (UTI)
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Others
By Application
- Drug-Resistance Testing
- Disease Testing
By Test Type
- Molecular Diagnostics
- Immunoassay
- Urinalysis
By End User
- Hospital
- Standalone Laboratories
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Hospital-Acquired Infection Diagnostics Market by Product
Chapter 5. North America Hospital-Acquired Infection Diagnostics Market by Infection Type
Chapter 6. North America Hospital-Acquired Infection Diagnostics Market by Application
Chapter 7. North America Hospital-Acquired Infection Diagnostics Market by Test Type
Chapter 8. North America Hospital-Acquired Infection Diagnostics Market by End User
Chapter 9. North America Hospital-Acquired Infection Diagnostics Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Methodology
LOADING...
